Application of tacrolimus in the treatment of skin diseases other than atopic dermatitis

Postepy Dermatologii i Alergologii

Volumn 28, Issue 1, 2011, Pages 41-45

  Silny, Wojciech ^a   Sadowska, Anna ^a   Dańczak Pazdrowska, Aleksandra ^a   Polańska, Adriana ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Calcineurin inhibitors; Skin diseases; Tacrolimus

Indexed keywords

BETAMETHASONE; CALCINEURIN; CALCIPOTRIOL; CALCIUM ION; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 3; TACROLIMUS; TETRACYCLINE; TRANSFORMING GROWTH FACTOR BETA;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; APPLICATION SITE BURNING; ATOPIC DERMATITIS; BULLOUS DERMATITIS; BULLOUS PEMPHIGOID; BURN; DERMATOLOGY; DRUG EFFICACY; ECZEMA; GRANULOMA ANNULARE; HUMAN; INCONTINENTIA PIGMENTI; KELOID; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LOCALIZED SCLERODERMA; LUPUS ERYTHEMATOSUS; NECROBIOSIS LIPOIDICA; PEMPHIGUS; PITYRIASIS; PRURITUS; PSORIASIS VULGARIS; PYODERMA GANGRENOSUM; QUALITY OF LIFE; REVIEW; ROSACEA; SARCOIDOSIS; SEBORRHEIC DERMATITIS; SKIN DISEASE; ULCER; VITILIGO;

EID: 79952431603     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Drake LA, Dinehart SM., Farmer ER, et al. Guidelines for care for the use of topical glucocorticoids. J Am Acad Dermatol 1996; 35: 615-9. (Pubitemid 26427069)
2. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987; 40: 1256-65. (Pubitemid 17138110)
3. Nakagawa H , Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 24, 344: 883.
4. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006. (Pubitemid 30629127)
5. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637-44.
6. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-64.
7. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-57.
8. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139: 1184-6. (Pubitemid 37128381)
9. Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat 2010; 21: 34-44.
10. Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 1999; 288: 653-9. (Pubitemid 29119677)
11. Czarnecka-Operacz M, Silny W. Nowe leki w miejscowej terapii atopowego zapalenia skóry. Pol Merk Lek 2003; 84: 682-4. (Pubitemid 36875024)
12. Fleischer AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-70.
13. Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venerol 2005; 19: 663-71. (Pubitemid 41748107)
14. Lesiak A, Kopeć A, Chruściel A, et al. Wyprysk opryszczkowaty Kaposiego u dziecka z atopowym zapaleniem skóry w trakcie leczenia pimekrolimusem (1% krem). Post Dermatol Alergol 2010; 27: 135-9.
15. Nowicki R. Co nowego w leczeniu atopowego zapalenia skóry? Post Dermatol Alergol 2009; 26: 350-3.
16. Zonneveld IM, Rubins A, Jabłońska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134: 1101-2. (Pubitemid 28432323)
17. Remiz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141: 101-7.
18. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564-8.
19. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-30. (Pubitemid 39516886)
20. Ezquerra GM, Sanchez R, Herrera Acosta E, et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corpolar plaques. J Drugs Dermatol 2006; 5: 334.
21. Brune A, Miller DW, Lin P et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007; 24: 76-80.
22. Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007; 157: 1005-12. (Pubitemid 47583535)
23. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-59.
24. Braza TJ, DiCarlo JB, Soon SL, et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003; 148: 1242-4. (Pubitemid 36819226)
25. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145-7. (Pubitemid 36801654)
26. Kamińska-Winciorek G, Brzezińska-Wcisło L. Miejscowe stosowanie takrolimusu jako alternatywna terapia łojotokowego zapalenia skóry - badanie pilotażowe. Post Dermatol Algol 2007; 5: 211-4. (Pubitemid 350200450)
27. Nagagawa H, Etoh T, Dakota Y, et al. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest 1996; 12: 245-50.
28. Vente C, Reich K, Rupprecht R, et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999; 140: 338-42. (Pubitemid 29111368)
29. Rozycki TW, Rogers RS, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002; 46: 27-34. (Pubitemid 34073474)
30. Kaliakatsou F, Hodgson TA, Lewsey JD, et al. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002; 46: 35-41. (Pubitemid 34073475)
31. Kirtschig G, Van Der Meulen AJ, Ion Lipan JW, et al. successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. Br J Dermatol 2002; 147: 625-6.
32. Watsky K. Erosive perianal lichen planus responsive to tacrolimus. Int J Dermatol 2003; 42: 217-8.
33. Virgili A, Lauriola MM, Mantovani L, et al. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0,1 % ointment. Acta Derm Venereol 2007; 87: 69-72. (Pubitemid 46225394)
34. Wolska H, Błaszczyk M. Takrolimus i pimekrolimus w dermatologii. Cz. II. Leczenie innych niż AZS chorób skóry. Przegl Dermatol 2004; 91: 371-82. (Pubitemid 39593212)
35. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-3.
36. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91. (Pubitemid 35239348)
37. Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-4. (Pubitemid 36576372)
38. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-62. (Pubitemid 38010838)
39. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5. (Pubitemid 36576373)
40. Castendo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet- B-narrow-band. Photodermatol Photoimmunol Photomed 2003; 19: 35-6. (Pubitemid 36621677)
41. Baldo A, Casula L, Prizio E, et al. Topical tacrolimus and vitiligo: our experience in sixty cases. Gital Dermatol Venereol 2007; 142: 621-5. (Pubitemid 351204542)
42. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-5. (Pubitemid 38313998)
43. Mancuso G, Berdondini RM. Topical Tacrolimus in the treatment of localized scleroderma. Eur J Dermatol 2003; 13: 590-2. (Pubitemid 38030805)
44. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005; 152: 180-2.
45. Rodriguez Rilo HL, Subbotin VM, Selby RR, Thomson AW. Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK506) therapy. Transplantation 1995; 59: 1350-3.
46. Thiers BH. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000; 136: 124. (Pubitemid 30038834)
47. Feldmann KA, Kunte C, Wollenberg A, et al. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002; 147: 1031-2.
48. Thomas J. A study of topical tacrolimus in alopecia areata in children. International Congress of Dermatology, Prague 2009.
49. Saleem A, Khan M, Mashori GR, et al. Comparison of effectiveness of topical tacrolimus and betamethasone with soft paraffin in the treatment of patchy alopecia areata. Pak J Med Sci 2009; 25: 833-6.
50. Dissemond J, Knab J, Lehnen M, et al. Successful treatment of stasis dermatitis with topical tacrolimus. Vasa 2004; 33: 260-2. (Pubitemid 39576893)
51. Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis 2008; 58: 299-306. (Pubitemid 351537620)
52. Schauber J, Weisenseel P, Ruzicka T. Topical treatment of perianal eczema with tacrolimus 0.1%. Br J Dermatol 2009; 161: 1384-6.
53. Bohm M, Gaubitz M, Luger TA, et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 2003; 207: 381-5. (Pubitemid 37505787)
54. Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology 2004; 43: 1383-5. (Pubitemid 39480924)
55. Sugano M, Shintani Y, Kobayashi K, et al. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2003; 33: 887-91.
56. Bansal Ch, Ross AS, Cusack CA. Chronic cutaneous lupus in childhood: a report of two cases and review of the literature. Int J Dermatol 2008; 47: 525-6. (Pubitemid 351560325)
57. Wons A, Haust M, Schneider SW, et al. Efficacy o tacrolimus 0.1% ointment in cutaneous lupus erythematosus - a multicenter, randomized, double-blind, vehicle-controlled trial of 30 patients. Congress of the European Academy of Dermatology and Venereology, Paris 2008.
58. Pabby A, KP An, Laws RA. Combination therapy of tetracycline and tacrolimus resulting in rapid resolution of steroidinduced periocular rosacea. Cutis 2003; 72: 141-2. (Pubitemid 37229744)
59. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50: 107-8. (Pubitemid 38095664)
60. Antille Ch, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 2004; 140: 457-60. (Pubitemid 38469249)
61. Fujiwara S, Okubo Y, Irisawa R, et al. Rosaceiform dermatitis associated with topical tacrolimus treatment. J Am Acad Dermatol 2010; 62: 1050-2.
62. Hall VC, Liesegang TJ, Kostick DA, et al. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139: 1083-4. (Pubitemid 36994841)
63. Vecchietti G, Kerl K, Hugli A, et al. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br J Dermatol 2003; 148: 833-4. (Pubitemid 36629777)
64. Gunther C, Wozel G, Meurer M, et al. Topical tacrolimus treatment for cicatrial pemphigoid. J Am Academ Dermatol 2004; 50: 325-6. (Pubitemid 38174302)
65. Calcaterra R, Carducci M, Franco G, et al. Topical tacrolimus treatment for localized pretibial bullous phemphigoid. J Eur Acad Dermatol Venereol 2009; 23: 177-9.
66. Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK506 in the treatment of recalcitrant pyoderma gangrenosum. Transplan Proc 1991; 23: 3328-9.
67. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139: 755-7.
68. Chandrasekhara PKS, Jayachadran NV, Thomas J, et al. Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol 2009; 28: 489-90.
69. Stander S, Schurmeyer-Horst F, Luger TA, et al. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006; 2: 213-8. (Pubitemid 43950058)